Direct-to-consumer genomic testing concerns explored

February 18, 2014
Direct-to-consumer genomic testing concerns explored

(HealthDay)—Various concerns relate to direct-to-consumer genomic testing, according to an ideas and opinions piece published online Feb. 10 in the Annals of Internal Medicine.

In August 2013, the company 23andMe launched an advertising campaign to sell its Personal Genome Service (PGS). Michael F. Murray, M.D., from the Geisinger Health System in Danville, Pa., discusses the U.S. Food and Drug Administration warning letter issued to 23andMe to discontinue marketing the PGS until it received FDA approval.

The author explains that 23andMe receives DNA samples in the mail and provides detailed analyses of for consumers, including reports on 254 diseases and conditions. However, these reports are mainly based on genome-wide association studies. For most of the conditions in the reports, there is no evidence that the results of the association studies can be applied as appropriate screening tests. In addition, concerns relating to direct-to-consumer PGS include economic concerns, such as increased for managing patients post-testing, and a concern that overregulation may limit innovation in this arena.

"Physicians should push for the building of patient-centered infrastructure to assist them in delivering valid genome-directed care as it develops," the author writes. "As for 23andMe, it would seem logical for the company to invest in research that determines the actual clinical value of their tests, and they should be expected to meet the same evidence standards as other device manufacturers under FDA jurisdiction."

Explore further: US tells 23andMe to halt sales of genetic test

More information: Full Text (subscription or payment may be required)

Related Stories

US tells 23andMe to halt sales of genetic test

November 25, 2013

The U.S. Food and Drug Administration is ordering genetic test maker 23andMe to halt sales of its personalized DNA test kits, saying the company has failed to show that the technology is backed by science.

It is game over for 23andMe, and rightly so

November 27, 2013

The market for personal genome services is facing a reality check. While the most prominent and innovative company 23andMe has flourished so far, in the past few years many of its competitors have gone out of business. Now, ...

Academics decry FDA crackdown on genome service companies

January 16, 2014

(Medical Xpress)—Dr. Robert Green, a medical geneticist with Brigham and Women's Hospital and Nita Farahany, professor of genome sciences and policy at Duke University, who also happens to be a lawyer have stepped into ...

11 new genetic associations for asthma-with-hay fever

January 28, 2014

23andMe has participated in the first ever genome-wide association study of the combined asthma-with-hay fever phenotype. Led by researchers at the QIMR Berghofer Medical Research Institute, the study identified 11 independent ...

Recommended for you

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.